{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:31:11Z","timestamp":1793399471593,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The study was supported by an unrestricted grant from Novo Nordisk. The sponsor has no role in the preparation of this article","award":["The study was supported by an unrestricted grant from Novo Nordisk. The sponsor has no role in the preparation of this article"],"award-info":[{"award-number":["The study was supported by an unrestricted grant from Novo Nordisk. The sponsor has no role in the preparation of this article"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-026-03007-x","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:42:58Z","timestamp":1786167778000},"page":"3267-3278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiological and socio-economic burden of MASH (previously known as NASH) in Europe: a systematic literature review"],"prefix":"10.1007","volume":"49","author":[{"given":"Ippazio Cosimo","family":"Antonazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-7446","authenticated-orcid":false,"given":"Giorgia","family":"Gribaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Miele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Paz","family":"Barboza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Perseghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Giovanni","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Angelo","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"3007_CR1","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.29607","volume":"67","author":"MS Siddiqui","year":"2018","unstructured":"Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L et al (2018) Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology 67:2001\u20132012. https:\/\/doi.org\/10.1002\/hep.29607","journal-title":"Hepatology"},{"key":"3007_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","volume":"33","author":"VW-S Wong","year":"2018","unstructured":"Wong VW-S, Chan W-K, Chitturi S, Chawla Y, Dan YY, Duseja A et al (2018) Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol 33:70\u201385. https:\/\/doi.org\/10.1111\/jgh.13857","journal-title":"J Gastroenterol Hepatol"},{"key":"3007_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"3007_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) (2016) European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388\u20131402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"key":"3007_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78:1966\u20131986. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"3007_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"3007_CR7","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y et al (2022) 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 20:2809\u20132817e28. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.002","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3007_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y et al (2020) Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 5:739\u2013752. https:\/\/doi.org\/10.1016\/S2468-1253(20)30077-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3007_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 7:851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3007_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"3007_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.14309\/ajg.0000000000001591","volume":"117","author":"L Yuan","year":"2022","unstructured":"Yuan L, Hanlon CL, Terrault N, Alqahtani S, Tamim H, Lai M et al (2022) Portrait of Regional Trends in Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. Am J Gastroenterol 117:433\u2013444. https:\/\/doi.org\/10.14309\/ajg.0000000000001591","journal-title":"Am J Gastroenterol"},{"key":"3007_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","volume":"71","author":"D Haldar","year":"2019","unstructured":"Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G et al (2019) Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol 71:313\u2013322. https:\/\/doi.org\/10.1016\/j.jhep.2019.04.011","journal-title":"J Hepatol"},{"key":"3007_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/hepr.13364","volume":"49","author":"K Umeshita","year":"2019","unstructured":"Umeshita K, Eguchi S, Egawa H, Haga H, Kasahara M, Kokudo N et al (2019) Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society. Hepatol Res 49:964\u2013980. https:\/\/doi.org\/10.1111\/hepr.13364","journal-title":"Hepatol Res"},{"key":"3007_CR14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65:1557\u20131565. https:\/\/doi.org\/10.1002\/hep.29085","journal-title":"Hepatology"},{"key":"3007_CR15","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1111\/liv.13743","volume":"38","author":"S Petta","year":"2018","unstructured":"Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Crax\u00ec A et al (2018) Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver Int 38:2060\u20132068. https:\/\/doi.org\/10.1111\/liv.13743","journal-title":"Liver Int"},{"key":"3007_CR16","doi-asserted-by":"publisher","unstructured":"Ciardullo S, Morabito G, Rea F, Savar\u00e9 L, Perseghin G, Corrao G (2024) Time trends in liver-related mortality in people with and without diabetes: Results from a population based study. J Clin Endocrinol Metab dgae182. https:\/\/doi.org\/10.1210\/clinem\/dgae182","DOI":"10.1210\/clinem\/dgae182"},{"key":"3007_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.numecd.2020.02.016","volume":"30","author":"S Petta","year":"2020","unstructured":"Petta S, Ting J, Saragoni S, Degli Esposti L, Shreay S, Petroni ML et al (2020) Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutr Metab Cardiovasc Dis 30:1014\u20131022. https:\/\/doi.org\/10.1016\/j.numecd.2020.02.016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"3007_CR18","doi-asserted-by":"crossref","unstructured":"Boursier J, Fabron C, Lafuma A, Bureau I (2018) NAFLD\/NASH patients with compensated cirrhosis (CC) had a high prevalence of comorbidities, substantial liver disease progression, and increased annual number of hospitalizations and associated costs in France: a PMSI database analysis, n.d. https:\/\/doi.org\/J Hepatol ;68:S820","DOI":"10.1016\/S0168-8278(18)31913-5"},{"key":"3007_CR19","doi-asserted-by":"crossref","unstructured":"Canbay A, Meise D, Haas JS (2018) Substantial comorbidities and rising economic burden in real-world non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC): a large German claims database study, n.d. https:\/\/doi.org\/J Hepatol ;68:S32","DOI":"10.1016\/S0168-8278(18)30282-4"},{"key":"3007_CR20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cgh.2019.10.023","volume":"18","author":"H Hagstr\u00f6m","year":"2020","unstructured":"Hagstr\u00f6m H, Nasr P, Ekstedt M, Hammar U, Widman L, St\u00e5l P et al (2020) Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. Clin Gastroenterol Hepatol 18:1592\u20131599e8. https:\/\/doi.org\/10.1016\/j.cgh.2019.10.023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3007_CR21","doi-asserted-by":"publisher","first-page":"100525","DOI":"10.1016\/j.jhepr.2022.100525","volume":"4","author":"Z Younossi","year":"2022","unstructured":"Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M et al (2022) The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep 4:100525. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100525","journal-title":"JHEP Rep"},{"key":"3007_CR22","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/hep.22868","volume":"49","author":"K David","year":"2009","unstructured":"David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB et al (2009) Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 49:1904\u20131912. https:\/\/doi.org\/10.1002\/hep.22868","journal-title":"Hepatology"},{"key":"3007_CR23","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/liv.15930","volume":"44","author":"S Petta","year":"2024","unstructured":"Petta S, Targher G, Romeo S, Pajvani UB, Zheng M-H, Aghemo A et al (2024) The first MASH drug therapy on the horizon: Current perspectives of resmetirom. Liver Int 44:1526\u20131536. https:\/\/doi.org\/10.1111\/liv.15930","journal-title":"Liver Int"},{"key":"3007_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ, Resmetirom (2024) First Approval Drugs 84:729\u2013735. https:\/\/doi.org\/10.1007\/s40265-024-02045-0","journal-title":"First Approval Drugs"},{"key":"3007_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41587-023-01787-8","volume":"41","author":"E Dolgin","year":"2023","unstructured":"Dolgin E (2023) NASH therapies head toward landmark approval. Nat Biotechnol 41:587\u2013590. https:\/\/doi.org\/10.1038\/s41587-023-01787-8","journal-title":"Nat Biotechnol"},{"key":"3007_CR26","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu V, Francque S, Sanyal A (2022) Breakthroughs in therapies for NASH and remaining challenges. J Hepatol 76:1263\u20131278. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.002","journal-title":"J Hepatol"},{"key":"3007_CR27","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","volume":"71","author":"J-F Dufour","year":"2022","unstructured":"Dufour J-F, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V et al (2022) Current therapies and new developments in NASH. Gut 71:2123\u20132134. https:\/\/doi.org\/10.1136\/gutjnl-2021-326874","journal-title":"Gut"},{"key":"3007_CR28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.cgh.2021.03.005","volume":"20","author":"IA Rowe","year":"2022","unstructured":"Rowe IA, Wong VW-S, Loomba R (2022) Treatment Candidacy for Pharmacologic Therapies for NASH. Clin Gastroenterol Hepatol 20:1209\u20131217. https:\/\/doi.org\/10.1016\/j.cgh.2021.03.005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3007_CR29","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3007_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40273-022-01140-y","volume":"40","author":"M Witkowski","year":"2022","unstructured":"Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S (2022) The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review. PharmacoEconomics 40:751\u2013776. https:\/\/doi.org\/10.1007\/s40273-022-01140-y","journal-title":"PharmacoEconomics"},{"key":"3007_CR31","unstructured":"Wells, George & Shea, Beverley & O\u2019Connell, D & Peterson, je & Welch, Vivian &Losos, M & Tugwell, Peter. The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. (2000). n.d."},{"key":"3007_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/jre.13405","author":"MC Carra","year":"2025","unstructured":"Carra MC, Romandini P, Romandini M (2025) Risk of Bias Evaluation of Cross-Sectional Studies: Adaptation of the Newcastle-Ottawa Scale. J Periodontal Res. https:\/\/doi.org\/10.1111\/jre.13405","journal-title":"J Periodontal Res"},{"key":"3007_CR33","doi-asserted-by":"publisher","unstructured":"Keykha E, Hajisadeghi S, Heidari MT The effect of dental rehabilitation under general anesthesia on dental anxiety in children: a systematic review and meta-analysis. BMC Oral Health 2025;25:1953. https:\/\/doi.org\/10.1186\/s12903-025-07334-y","DOI":"10.1186\/s12903-025-07334-y"},{"key":"3007_CR34","unstructured":"Drummond checklist URL: https:\/\/www.ispor.org\/docs\/default-source\/euro2024\/quality-assessmentdrummond-10-checklist146510-pdf.pdf?sfvrsn=c404f85_0n.d"},{"key":"3007_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jhep.2013.12.009","volume":"60","author":"J Hyysalo","year":"2014","unstructured":"Hyysalo J, M\u00e4nnist\u00f6 VT, Zhou Y, Arola J, K\u00e4rj\u00e4 V, Leivonen M et al (2014) A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 60:839\u2013846. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.009","journal-title":"J Hepatol"},{"key":"3007_CR36","doi-asserted-by":"publisher","first-page":"101363","DOI":"10.1016\/j.diabet.2022.101363","volume":"48","author":"E Lembo","year":"2022","unstructured":"Lembo E, Russo MF, Verrastro O, Anello D, Angelini G, Iaconelli A et al (2022) Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes. Diabetes Metab 48:101363. https:\/\/doi.org\/10.1016\/j.diabet.2022.101363","journal-title":"Diabetes Metab"},{"key":"3007_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13104-015-1224-7","volume":"8","author":"A Hillenbrand","year":"2015","unstructured":"Hillenbrand A, Kiebler B, Schwab C, Scheja L, Xu P, Henne-Bruns D et al (2015) Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors. BMC Res Notes 8:290. https:\/\/doi.org\/10.1186\/s13104-015-1224-7","journal-title":"BMC Res Notes"},{"key":"3007_CR38","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.soard.2020.07.009","volume":"16","author":"S Frey","year":"2020","unstructured":"Frey S, Patouraux S, Debs T, Gugenheim J, Anty R, Iannelli A (2020) Prevalence of NASH\/NAFLD in people with obesity who are currently classified as metabolically healthy. Surg Obes Relat Dis 16:2050\u20132057. https:\/\/doi.org\/10.1016\/j.soard.2020.07.009","journal-title":"Surg Obes Relat Dis"},{"key":"3007_CR39","doi-asserted-by":"publisher","first-page":"5023157","DOI":"10.1155\/2020\/5023157","volume":"2020","author":"M Soresi","year":"2020","unstructured":"Soresi M, Cabibi D, Giglio RV, Martorana S, Guercio G, Porcasi R et al (2020) The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods. Biomed Res Int 2020:5023157. https:\/\/doi.org\/10.1155\/2020\/5023157","journal-title":"Biomed Res Int"},{"key":"3007_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.hipert.2018.10.001","volume":"36","author":"R Garc\u00eda-Carretero","year":"2019","unstructured":"Garc\u00eda-Carretero R, Barquero-P\u00e9rez O, Mora-Jim\u00e9nez I, Soguero-Ruiz C, Goya-Esteban R, Rodr\u00edguez-Castro C et al (2019) [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population]. Hipertens Riesgo Vasc 36:130\u2013136. https:\/\/doi.org\/10.1016\/j.hipert.2018.10.001","journal-title":"Hipertens Riesgo Vasc"},{"key":"3007_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.aprim.2015.06.006","volume":"48","author":"MA Samperio-Gonz\u00e1lez","year":"2016","unstructured":"Samperio-Gonz\u00e1lez MA, Selvi-Blasco M, Manzano-Montero M, M\u00e9ndez-G\u00f3mez J, Gil-Prades M, Azagra R (2016) [Prevalence of non-alcoholic fatty liver disease in a population with elevated transaminases and level of accuracy of the diagnosis in Primary Care]. Aten Primaria 48:281\u2013287. https:\/\/doi.org\/10.1016\/j.aprim.2015.06.006","journal-title":"Aten Primaria"},{"key":"3007_CR42","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s11605-013-2149-x","volume":"17","author":"SK Reddy","year":"2013","unstructured":"Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S et al (2013) Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg 17:748\u2013755. https:\/\/doi.org\/10.1007\/s11605-013-2149-x","journal-title":"J Gastrointest Surg"},{"key":"3007_CR43","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2337\/dc22-2048","volume":"46","author":"L Castera","year":"2023","unstructured":"Castera L, Laouenan C, Vallet-Pichard A, Vidal-Tr\u00e9can T, Manchon P, Paradis V et al (2023) High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold. Diabetes Care 46:1354\u20131362. https:\/\/doi.org\/10.2337\/dc22-2048","journal-title":"Diabetes Care"},{"key":"3007_CR44","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/QAD.0000000000003312","volume":"36","author":"M Michel","year":"2022","unstructured":"Michel M, Labenz C, Wahl A, Anders M, Armandi A, Huber Y et al (2022) Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV. AIDS 36:1665\u20131674. https:\/\/doi.org\/10.1097\/QAD.0000000000003312","journal-title":"AIDS"},{"key":"3007_CR45","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/liv.12813","volume":"35","author":"C Garc\u00eda-Monz\u00f3n","year":"2015","unstructured":"Garc\u00eda-Monz\u00f3n C, Vargas-Castrill\u00f3n J, Porrero JL, Alonso MT, Bonach\u00eda O, Castillo MJ et al (2015) Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. Liver Int 35:1983\u20131991. https:\/\/doi.org\/10.1111\/liv.12813","journal-title":"Liver Int"},{"key":"3007_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/MEG.0000000000001270","volume":"31","author":"B Kern","year":"2019","unstructured":"Kern B, Feurstein B, Fritz J, Fabritius C, Sucher R, Graziadei I et al (2019) High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. Eur J Gastroenterol Hepatol 31:205\u2013210. https:\/\/doi.org\/10.1097\/MEG.0000000000001270","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3007_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4254\/wjh.v11.i4.391","volume":"11","author":"G Damiani","year":"2019","unstructured":"Damiani G, Leone S, Fajgenbaum K, Bragazzi NL, Pacifico A, Conic RR et al (2019) Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis. World J Hepatol 11:391\u2013401. https:\/\/doi.org\/10.4254\/wjh.v11.i4.391","journal-title":"World J Hepatol"},{"key":"3007_CR48","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J et al (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol 69:896\u2013904. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.036","journal-title":"J Hepatol"},{"key":"3007_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00268-022-06781-w","volume":"47","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Donlon NE, Elliott JA, Moran B, Temperley H, Nugent TS et al (2023) Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. World J Surg 47:227\u2013235. https:\/\/doi.org\/10.1007\/s00268-022-06781-w","journal-title":"World J Surg"},{"key":"3007_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/liv.15730","volume":"44","author":"R Forlano","year":"2024","unstructured":"Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Mossialos E et al (2024) A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int 44:61\u201371. https:\/\/doi.org\/10.1111\/liv.15730","journal-title":"Liver Int"},{"key":"3007_CR51","doi-asserted-by":"publisher","first-page":"101497","DOI":"10.1016\/j.diabet.2023.101497","volume":"50","author":"A Mantovani","year":"2024","unstructured":"Mantovani A, Morieri ML, Aldigeri R, Palmisano L, Masulli M, Bonomo K et al (2024) MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus. Diabetes Metab 50:101497. https:\/\/doi.org\/10.1016\/j.diabet.2023.101497","journal-title":"Diabetes Metab"},{"key":"3007_CR52","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s40618-021-01501-y","volume":"44","author":"ML Morieri","year":"2021","unstructured":"Morieri ML, Vitturi N, Avogaro A, Targher G, Fadini GP, Consoli A et al (2021) Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. J Endocrinol Invest 44:1879\u20131889. https:\/\/doi.org\/10.1007\/s40618-021-01501-y","journal-title":"J Endocrinol Invest"},{"key":"3007_CR53","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.14218\/JCTH.2023.00117","volume":"11","author":"Q Binet","year":"2023","unstructured":"Binet Q, Loumaye A, Hermans MP, Lanthier N (2023) A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients. J Clin Transl Hepatol 11:1377\u20131386. https:\/\/doi.org\/10.14218\/JCTH.2023.00117","journal-title":"J Clin Transl Hepatol"},{"key":"3007_CR54","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.dld.2016.08.117","volume":"48","author":"R Lombardi","year":"2016","unstructured":"Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA (2016) Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis 48:1471\u20131477. https:\/\/doi.org\/10.1016\/j.dld.2016.08.117","journal-title":"Dig Liver Dis"},{"key":"3007_CR55","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.3390\/jcm12237276","volume":"12","author":"J Rivera-Esteban","year":"2023","unstructured":"Rivera-Esteban J, Jim\u00e9nez-Masip A, Mu\u00f1oz-Mart\u00ednez S, Augustin S, Guerrero RA, Gabriel-Medina P et al (2023) Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study. J Clin Med 12:7276. https:\/\/doi.org\/10.3390\/jcm12237276","journal-title":"J Clin Med"},{"key":"3007_CR56","doi-asserted-by":"publisher","unstructured":"Pelusi S, Ronzoni L, Rondena J, Rosso C, Pennisi G, Dongiovanni P et al Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD. Clin Gastroenterol Hepatol 2024:S1542-3565(24)00046\u2009\u2013\u20096. https:\/\/doi.org\/10.1016\/j.cgh.2023.12.033","DOI":"10.1016\/j.cgh.2023.12.033"},{"key":"3007_CR57","doi-asserted-by":"publisher","first-page":"1003878","DOI":"10.3389\/fendo.2022.1003878","volume":"13","author":"L Canillas","year":"2022","unstructured":"Canillas L, Soriano-Varela A, Rodr\u00edguez-Campello A, Giralt-Steinhauer E, Cuadrado-Godia E, Broquetas T (2022) High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death. Front Endocrinol (Lausanne) 13:1003878. https:\/\/doi.org\/10.3389\/fendo.2022.1003878","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3007_CR58","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3390\/diagnostics11122341","volume":"11","author":"R Nastasa","year":"2021","unstructured":"Nastasa R, Stanciu C, Zenovia S, Singeap A-M, Cojocariu C, Sfarti C et al (2021) The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. Diagnostics (Basel) 11:2341. https:\/\/doi.org\/10.3390\/diagnostics11122341","journal-title":"Diagnostics (Basel)"},{"key":"3007_CR59","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/liv.15761","volume":"44","author":"CW Wernberg","year":"2024","unstructured":"Wernberg CW, Kjer MF, Gr\u00f8nkjaer LL, Jacobsen BG, Lauridsen MM (2024) Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study. Liver Int 44:191\u2013201. https:\/\/doi.org\/10.1111\/liv.15761","journal-title":"Liver Int"},{"key":"3007_CR60","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s44197-023-00109-0","volume":"13","author":"G Cao","year":"2023","unstructured":"Cao G, Liu J, Liu M, Global (2023) Regional, and National Trends in Incidence and Mortality of Primary Liver Cancer and Its Underlying Etiologies from 1990 to 2019: Results from the Global Burden of Disease Study 2019. J Epidemiol Glob Health 13:344\u2013360. https:\/\/doi.org\/10.1007\/s44197-023-00109-0","journal-title":"J Epidemiol Glob Health"},{"key":"3007_CR61","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF (2021) Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70:1375\u20131382. https:\/\/doi.org\/10.1136\/gutjnl-2020-322786","journal-title":"Gut"},{"key":"3007_CR62","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jhep.2021.06.034","volume":"75","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Hartjes K, Shah U, Khalili H, Arnell H et al (2021) Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol 75:1034\u20131041. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.034","journal-title":"J Hepatol"},{"key":"3007_CR63","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/apt.15255","volume":"49","author":"E Nilsson","year":"2019","unstructured":"Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H (2019) Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. Aliment Pharmacol Ther 49:1421\u20131430. https:\/\/doi.org\/10.1111\/apt.15255","journal-title":"Aliment Pharmacol Ther"},{"key":"3007_CR64","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.diabres.2017.07.030","volume":"132","author":"JE Carruthers","year":"2017","unstructured":"Carruthers JE, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP (2017) Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. Diabetes Res Clin Pract 132:102\u2013107. https:\/\/doi.org\/10.1016\/j.diabres.2017.07.030","journal-title":"Diabetes Res Clin Pract"},{"key":"3007_CR65","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.eclinm.2020.100445","volume":"25","author":"J Boursier","year":"2020","unstructured":"Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J (2020) Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine 25:100445. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100445","journal-title":"EClinicalMedicine"},{"key":"3007_CR66","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12916-023-02891-x","volume":"21","author":"TJ Hydes","year":"2023","unstructured":"Hydes TJ, Kennedy OJ, Buchanan R, Cuthbertson DJ, Parkes J, Fraser SDS et al (2023) The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. BMC Med 21:185. https:\/\/doi.org\/10.1186\/s12916-023-02891-x","journal-title":"BMC Med"},{"key":"3007_CR67","doi-asserted-by":"publisher","first-page":"e0241357","DOI":"10.1371\/journal.pone.0241357","volume":"15","author":"JP Mann","year":"2020","unstructured":"Mann JP, Carter P, Armstrong MJ, Abdelaziz HK, Uppal H, Patel B et al (2020) Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLoS ONE 15:e0241357. https:\/\/doi.org\/10.1371\/journal.pone.0241357","journal-title":"PLoS ONE"},{"key":"3007_CR68","doi-asserted-by":"publisher","first-page":"16559","DOI":"10.1038\/s41598-018-34988-2","volume":"8","author":"D Viglino","year":"2018","unstructured":"Viglino D, Plazanet A, Bailly S, Benmerad M, Jullian-Desayes I, Tamisier R et al (2018) Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease. Sci Rep 8:16559. https:\/\/doi.org\/10.1038\/s41598-018-34988-2","journal-title":"Sci Rep"},{"key":"3007_CR69","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12885-015-1197-x","volume":"15","author":"A Weinmann","year":"2015","unstructured":"Weinmann A, Alt Y, Koch S, Nelles C, D\u00fcber C, Lang H et al (2015) Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 15:210. https:\/\/doi.org\/10.1186\/s12885-015-1197-x","journal-title":"BMC Cancer"},{"key":"3007_CR70","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.cgh.2015.10.010","volume":"14","author":"N Goossens","year":"2016","unstructured":"Goossens N, Hoshida Y, Song WM, Jung M, Morel P, Nakagawa S et al (2016) Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clin Gastroenterol Hepatol 14:1619\u20131628. https:\/\/doi.org\/10.1016\/j.cgh.2015.10.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3007_CR71","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.clnu.2024.02.006","volume":"43","author":"M Kouvari","year":"2024","unstructured":"Kouvari M, Chrysohoou C, Damigou E, Barkas F, Kravvariti E, Liberopoulos E et al (2024) Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002\u20132022). Clin Nutr 43:900\u2013908. https:\/\/doi.org\/10.1016\/j.clnu.2024.02.006","journal-title":"Clin Nutr"},{"key":"3007_CR72","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1007\/s10620-019-06000-y","volume":"65","author":"LW Unger","year":"2020","unstructured":"Unger LW, Forstner B, Muckenhuber M, Scheuba K, Eigenbauer E, Scheiner B et al (2020) Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. Dig Dis Sci 65:2712\u20132718. https:\/\/doi.org\/10.1007\/s10620-019-06000-y","journal-title":"Dig Dis Sci"},{"key":"3007_CR73","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/MEG.0000000000001105","volume":"30","author":"S Gitto","year":"2018","unstructured":"Gitto S, de Maria N, di Benedetto F, Tarantino G, Serra V, Maroni L et al (2018) De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients. Eur J Gastroenterol Hepatol 30:766\u2013773. https:\/\/doi.org\/10.1097\/MEG.0000000000001105","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3007_CR74","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/liv.14825","volume":"41","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S et al (2021) Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int 41:1227\u20131242. https:\/\/doi.org\/10.1111\/liv.14825","journal-title":"Liver Int"},{"key":"3007_CR75","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","volume":"1","author":"M-M Balp","year":"2019","unstructured":"Balp M-M, Krieger N, Przybysz R, Way N, Cai J, Zappe D et al (2019) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. JHEP Rep 1:154\u2013161. https:\/\/doi.org\/10.1016\/j.jhepr.2019.05.009","journal-title":"JHEP Rep"},{"key":"3007_CR76","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cgh.2020.06.064","volume":"19","author":"A Geier","year":"2021","unstructured":"Geier A, Rinella ME, Balp M-M, McKenna SJ, Brass CA, Przybysz R et al (2021) Real-World Burden of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 19:1020\u20131029e7. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.064","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3007_CR77","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","volume":"2","author":"J O\u2019Hara","year":"2020","unstructured":"O\u2019Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B et al (2020) Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep 2:100142. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100142","journal-title":"JHEP Rep"},{"key":"3007_CR78","doi-asserted-by":"publisher","first-page":"111045","DOI":"10.1016\/j.jpsychores.2022.111045","volume":"162","author":"J Funuyet-Salas","year":"2022","unstructured":"Funuyet-Salas J, P\u00e9rez-San-Gregorio M\u00c1, Mart\u00edn-Rodr\u00edguez A, Romero-G\u00f3mez M (2022) Vitality, mental health and role-physical mediate the influence of coping on depressive symptoms and self-efficacy in patients with non-alcoholic fatty liver disease: A cross-sectional study. J Psychosom Res 162:111045. https:\/\/doi.org\/10.1016\/j.jpsychores.2022.111045","journal-title":"J Psychosom Res"},{"key":"3007_CR79","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/hep4.2044","volume":"6","author":"L Heath","year":"2022","unstructured":"Heath L, Aveyard P, Tomlinson JW, Cobbold JF, Koutoukidis DA (2022) Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. Hepatol Commun 6:2623\u20132633. https:\/\/doi.org\/10.1002\/hep4.2044","journal-title":"Hepatol Commun"},{"key":"3007_CR80","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","volume":"17","author":"Y Huber","year":"2019","unstructured":"Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C et al (2019) Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clin Gastroenterol Hepatol 17:2085\u20132092. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.016. e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3007_CR81","doi-asserted-by":"publisher","first-page":"585425","DOI":"10.3389\/fmed.2020.585425","volume":"7","author":"J Funuyet-Salas","year":"2020","unstructured":"Funuyet-Salas J, P\u00e9rez-San-Gregorio M\u00c1, Mart\u00edn-Rodr\u00edguez A, Romero-G\u00f3mez M (2020) Psychological Biomarkers and Fibrosis: An Innovative Approach to Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 7:585425. https:\/\/doi.org\/10.3389\/fmed.2020.585425","journal-title":"Front Med (Lausanne)"},{"key":"3007_CR82","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11136-022-03232-w","volume":"32","author":"M Michel","year":"2023","unstructured":"Michel M, Wahl A, Anders M, Alqahtani SA, Kremer WM, Galle PR et al (2023) Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV. Qual Life Res 32:401\u2013411. https:\/\/doi.org\/10.1007\/s11136-022-03232-w","journal-title":"Qual Life Res"},{"key":"3007_CR83","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ajg.2022.05.006","volume":"23","author":"ID Vachliotis","year":"2022","unstructured":"Vachliotis ID, Vasiloglou MF, Kapama A, Matsagkos D, Goulas A, Papaioannidou P et al (2022) Association between hepatic steatosis and fibrosis indices and dietary habits, physical activity, and quality of life. Arab J Gastroenterol 23:277\u2013287. https:\/\/doi.org\/10.1016\/j.ajg.2022.05.006","journal-title":"Arab J Gastroenterol"},{"key":"3007_CR84","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15403\/jgld-4275","volume":"31","author":"A Geier","year":"2022","unstructured":"Geier A, Heinz S, Balp M-M, Brass C, Pedrosa M, Cai J et al (2022) The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States. J Gastrointestin Liver Dis 31:317\u2013322. https:\/\/doi.org\/10.15403\/jgld-4275","journal-title":"J Gastrointestin Liver Dis"},{"key":"3007_CR85","doi-asserted-by":"publisher","unstructured":"Torre E, Di Matteo S, Bruno GM, Martinotti C, Valentino MC, Testino G, et al. Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. Clinicoecon Outcomes Res 2022;14:607\u201318. https:\/\/doi.org\/10.2147\/CEOR.S371778","DOI":"10.2147\/CEOR.S371778"},{"key":"3007_CR86","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s12325-019-00960-3","volume":"36","author":"M Povsic","year":"2019","unstructured":"Povsic M, Wong OY, Perry R, Bottomley J (2019) A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Adv Ther 36:1574\u20131594. https:\/\/doi.org\/10.1007\/s12325-019-00960-3","journal-title":"Adv Ther"},{"key":"3007_CR87","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3350\/cmh.2024.0109","volume":"30","author":"H Crane","year":"2024","unstructured":"Crane H, Eslick GD, Gofton C, Shaikh A, Cholankeril G, Cheah M et al (2024) Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Mol Hepatol 30:436\u2013448. https:\/\/doi.org\/10.3350\/cmh.2024.0109","journal-title":"Clin Mol Hepatol"},{"key":"3007_CR88","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/hep.32131","volume":"75","author":"LA van Kleef","year":"2022","unstructured":"van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ (2022) Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology 75:419\u2013429. https:\/\/doi.org\/10.1002\/hep.32131","journal-title":"Hepatology"},{"key":"3007_CR89","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.3390\/ijms242015473","volume":"24","author":"H Yanai","year":"2023","unstructured":"Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H (2023) Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments. Int J Mol Sci 24:15473. https:\/\/doi.org\/10.3390\/ijms242015473","journal-title":"Int J Mol Sci"},{"key":"3007_CR90","doi-asserted-by":"publisher","first-page":"100370","DOI":"10.1016\/j.jhepr.2021.100370","volume":"3","author":"LL Gr\u00f8nkj\u00e6r","year":"2021","unstructured":"Gr\u00f8nkj\u00e6r LL, Lauridsen MM (2021) Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review. JHEP Rep 3:100370. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100370","journal-title":"JHEP Rep"},{"key":"3007_CR91","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D et al (2021) MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 51:1115\u20131128. https:\/\/doi.org\/10.1111\/hepr.13685","journal-title":"Hepatol Res"},{"key":"3007_CR92","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13098-022-00887-w","volume":"14","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H et al (2022) MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr 14:115. https:\/\/doi.org\/10.1186\/s13098-022-00887-w","journal-title":"Diabetol Metab Syndr"},{"key":"3007_CR93","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/hepr.13973","volume":"54","author":"S Fukunaga","year":"2024","unstructured":"Fukunaga S, Mukasa M, Nakane T, Nakano D, Tsutsumi T, Chou T et al (2024) Impact of non-obese metabolic dysfunction-associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study. Hepatol Res 54:201\u2013212. https:\/\/doi.org\/10.1111\/hepr.13973","journal-title":"Hepatol Res"},{"key":"3007_CR94","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/hepr.14010","volume":"54","author":"T Nakane","year":"2024","unstructured":"Nakane T, Fukunaga S, Nakano D, Tsutsumi T, Tanaka H, Chou T et al (2024) Impact of metabolic dysfunction-associated fatty liver disease on the incidence of Helicobacter pylori-negative gastric cancer. Hepatol Res 54:540\u2013550. https:\/\/doi.org\/10.1111\/hepr.14010","journal-title":"Hepatol Res"},{"key":"3007_CR95","doi-asserted-by":"publisher","unstructured":"Guirguis E, Dougherty J, Thornby K, Grace Y, Mack K Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH). Ann Pharmacother 2024:10600280241259528. https:\/\/doi.org\/10.1177\/10600280241259528","DOI":"10.1177\/10600280241259528"},{"key":"3007_CR96","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al (2020) A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 73:202\u2013209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","journal-title":"J Hepatol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03007-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03007-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-03007-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:01:25Z","timestamp":1793397685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-03007-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":96,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3007"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-03007-x","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.C.A., G.G., L.Y., B.P. declare no conflicts of interest. P. A. C. has received a research grant from Baxalta, now part of Shire, and speaking honoraria from Pfizer and Roche. L. G. M. has received grants and personal fees from Bayer AG, Boehringer Ingelheim, Pfizer and Daiichi-Sankyo. L. M, acted as Scientific advisor or consultant for: Alfa-Sigma, Boehringer-Ingelheim, BMS, Echosens, Galmed, Gilead Sciences, GSK, IBSA, Intercept, MEDA, MyGenomics, Merck Sharp & Dohme, Novartis, Novo-Nordisk, Pfizer, ProLon, Promethera, Resalis, Rottapharm-Madaus, Siemens Healthineers, Synageva. S.F. acted as speaker and \/or advisor for Gilead, Abbvie, Advanz, Novonordisk, Bayer, MSD, Roche, Eisai, Kedrion, Novartis. S. P. acted as speaker and\/or advisor and\/or received grants from AbbVie, Echosens, Gilead, MSD, Novonordisk, Pfizer and Resalis. G.P. has received speaking honoraria from AstraZeneca, Bayer, Boheringer Ingelheim, Daiichi Sankyo, Echosens, Lilly, Menarini Diag, Merck, Novartis, Novo Nordisk, Pfizer, PikDare, Roche Diag, Sanofi, Servier and participation in Advisory Boards for Amgen, Bruno Farmaceutici, EG, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, PikDare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Informed consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Institutional Review Board Statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}